3-methoxy-1-(phenylmethyl)-4-piperidinone | 134473-73-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-methoxy-1-(phenylmethyl)-4-piperidinone
• 英文别名: 3-methoxy-1-(phenylmethyl)-4-piperidone；1-phenylmethyl-3-methoxy-4-piperidone；1-Benzyl-3-methoxypiperidin-4-one
• CAS: 134473-73-7
• 化学式: C₁₃H₁₇NO₂
• 分子量: 219.283
• InChiKey: BZJUOSKBRSTXDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-methoxy-1-(phenylmethyl)-4-piperidinone 在 镍 氨 作用下， 以 甲醇 为溶剂， 以78 parts (100%)的产率得到1-benzyl-3-methoxypiperidin-4-amine
  参考文献：
  名称：

  Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives

  摘要：

  新型N-(3-羟基-4-哌啶基)苯甲酰胺及其衍生物，所述化合物可用作促进胃肠系统运动的刺激剂。

  公开号：

  US04962115A1
• 作为产物：
  描述：

  1-phenylmethyl-3-methoxy-4,4-dimethoxypiperidine 在 硫酸 、 sodium carbonate 作用下， 以28.8 parts (98.6%)的产率得到3-methoxy-1-(phenylmethyl)-4-piperidinone
  参考文献：
  名称：

  Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives

  摘要：

  新型N-(3-羟基-4-哌啶基)苯甲酰胺及其衍生物，所述化合物可用作促进胃肠系统运动的刺激剂。

  公开号：

  US04962115A1

文献信息

• Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
  申请人：Janssen Pharmaceutical N.V.

  公开号：US04975439A1

  公开（公告）日：1990-12-04

  Substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides, their N-oxide forms, their pharmaceutically acceptable acid addition salts and stereochemically isomeric forms having gastrointestinal motility stimulating properties, compositions containing the same, and methods of treating warm-blooded animals suffering from motility disorders of the gastrointestinal system.

  取代N-(1-烷基-3-羟基-4-哌啶基)苯甲酰胺，其N-氧化物形式，其药用可接受的酸盐和具有促进胃肠蠕动性能的立体化异构体形式，含有这些物质的组合物，以及治疗患有胃肠系统蠕动障碍的温血动物的方法。
• Esters of 3-hydroxy-piperidinemethanol derivatives
  申请人：Janssen Pharmaceutica N.V.

  公开号：US06096761A1

  公开（公告）日：2000-08-01

  The present invention of compounds of formula (I), ##STR1## a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, R.sup.1 is C.sub.1-6 alkyloxy, C.sub.2-6 alkenyloxy or C.sub.2-6 alkynyloxy; R.sup.2 is hydrogen or C.sub.1-6 alkyloxy, or when taken together R.sup.1 and R.sup.2 may form a bivalent radical of formula wherein in said bivalent radicals one or two hydrogen atoms may be substituted with C.sub.1-6 alkyl; R.sup.3 is hydrogen or halo; R.sup.4 is hydrogen or C.sub.1-6 alkyl; L is C.sub.3-6 cycloalkyl, C.sub.5-6 cycloalkanone, C.sub.2-6 alkenyl optionally substituted with aryl, or L is a radical of formula -Alk-R.sup.5 -, Alk-X--R.sup.6, -Alk-Y--C(.dbd.O)--R.sup.8, or -Alk-Y--C(.dbd.O)--NR.sup.10 R.sup.11 wherein each Alk is C.sub.1-12 alkanediyl; and R.sup.5 is hydrogen, cyano, C.sub.1-6 alkylsulfonylamino, C.sub.3-6 cycloalkyl, C.sub.5-6 cycloalkanone, aryl, di(aryl)methyl or a heterocyclic ringsystem; R.sup.6 is hydrogen, C.sub.1-6 alkyl, hydroxyC.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, aryl or heterocyclic ringsystem; X is O, S, SO.sub.2 or NR.sup.7 ; said R.sub.7 being hydrogen, C.sub.1-6 alkyl or aryl; R.sup.8 is hydrogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, aryl, arylC.sub.1-6 alkyl, di(aryl)methyl, C.sub.1-6 alkyloxy or hydroxy; Y is NR.sup.9 or a direct bond; said R.sup.9 being hydrogen, C.sub.1-6 alkyl or aryl R.sup.10 and R.sup.11 each independently are hydrogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, aryl or arylC.sub.1-6 alkyl, or R.sup.10 and R.sup.11 combined with the nitrogen atom bearing R.sup.10 and R.sup.11 may form a pyrrolidinyl or piperidinyl ring both being optionally substituted with C.sub.1-6 alkyl, amino or mono or di(C.sub.1-6 alkyl)amino, or said R.sup.10 and R.sup.11 combined with the nitrogen bearing R.sup.10 and R.sup.11 may form a piperazinyl or 4-morpholinyl radical both being optionally substituted with C.sub.1-6 alkyl. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impairment of gastric emptying.

  本发明涉及化合物的公式（I），其立体化学异构体，N-氧化物形式或其药学上可接受的酸盐，其中R.sup.1为C.sub.1-6烷氧基，C.sub.2-6烯氧基或C.sub.2-6炔基氧基；R.sup.2为氢或C.sub.1-6烷氧基，或当R.sup.1和R.sup.2结合在一起时，可以形成一个具有以下结构的二价基团，其中在所述的二价基团中，一个或两个氢原子可以被C.sub.1-6烷基取代；R.sup.3为氢或卤素；R.sup.4为氢或C.sub.1-6烷基；L为C.sub.3-6环烷基，C.sub.5-6环戊酮，C.sub.2-6烯基，可选地取代芳基，或L为以下结构的基团-Alk-R.sup.5-，Alk-X--R.sup.6，-Alk-Y--C(.dbd.O)--R.sup.8或-Alk-Y--C(.dbd.O)--NR.sup.10R.sup.11，其中每个Alk为C.sub.1-12烷二基；R.sup.5为氢，氰基，C.sub.1-6烷基磺酰氨基，C.sub.3-6环烷基，C.sub.5-6环戊酮，芳基，二(芳基)甲基或杂环戒系统；R.sup.6为氢，C.sub.1-6烷基，羟基C.sub.1-6烷基，C.sub.3-6环烷基，芳基或杂环戒系统；X为O，S，SO.sub.2或NR.sup.7；其中R.sub.7为氢，C.sub.1-6烷基或芳基；R.sup.8为氢，C.sub.1-6烷基，C.sub.3-6环烷基，芳基，芳基C.sub.1-6烷基，二(芳基)甲基，C.sub.1-6烷氧基或羟基；Y为NR.sup.9或直接键；其中R.sup.9为氢，C.sub.1-6烷基或芳基，R.sup.10和R.sup.11各自独立地为氢，C.sub.1-6烷基，C.sub.3-6环烷基，芳基或芳基C.sub.1-6烷基，或R.sup.10和R.sup.11与携带R.sup.10和R.sup.11的氮原子结合，可以形成一个取代有C.sub.1-6烷基，氨基或单或二(C.sub.1-6烷基)氨基的吡咯烷基或哌啶烷基环，或R.sup.10和R.sup.11与携带R.sup.10和R.sup.11的氮原子结合，可以形成一个取代有C.sub.1-6烷基的哌嗪基或4-吗啉基基团。公开了制备所述产品的方法，包括所述产品的配方以及它们作为药物的用途，特别是用于治疗与胃排空障碍相关的疾病。
• Phenyl-oxo-alkyl-(4-piperidinyl)benzoate derivatives
  申请人：Janssen Pharmaceutica, N.V.

  公开号：US05872131A1

  公开（公告）日：1999-02-16

  The present invention is concerned with novel benzoate derivatives having the formula ##STR1## the N-oxide forms, the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein R.sup.1 is halo or C.sub.1-6 alkylsulfonylamino; either R.sup.2 is hydrogen and R.sup.3 is C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl; or R.sup.2 and R.sup.3 taken together form a bivalent radical of formula --CH.dbd.CH-- (a), --(CH.sub.2).sub.2 -- (b), or --(CH.sub.2).sub.3 -- (c); in the bivalent radicals of formula (a), (b) or (c) one or two hydrogen atoms may be replaced by C.sub.1-6 alkyl; Alk is C.sub.1-6 alkanediyl; R.sup.4 is hydrogen or C.sub.1-6 alkyloxy; R.sup.5, R.sup.6 and R.sup.7 each independently are hydrogen, halo, C.sub.1-6 alkyl, C.sub.1-6 alkyloxy; or R.sup.5 and R.sup.6 taken together may also form a bivalent radical of formula: --NR.sup.8 C(O)NR.sup.9 --, --NH--C(NHR.sup.10).dbd.N--, --O--(CH.sub.2).sub.m --O--; R.sup.8 and R.sup.9 each independently are hydrogen or C.sub.1-6 alkyl; R.sup.10 is hydrogen, C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkyloxycarbonyl; m is 1 or 2. Pharmaceutical compositions comprising said compounds, processes for preparing compounds and compositions as well as the use as a medicine, in particular for the treatment of intestinal disorders involving a decreased colon motility are described.

  本发明涉及具有以下结构式的新型苯甲酸酯衍生物：##STR1## 其中R.sup.1是卤素或C.sub.1-6烷基磺酰胺；R.sup.2是氢，R.sup.3是C.sub.1-6烷基，C.sub.2-6烯基或C.sub.2-6炔基；或者R.sup.2和R.sup.3一起形成下列结构式的二价基团：--CH.dbd.CH--（a），--(CH.sub.2).sub.2 --（b），或--(CH.sub.2).sub.3 --（c）；在结构式（a），（b）或（c）的二价基团中，一个或两个氢原子可以被C.sub.1-6烷基取代；Alk为C.sub.1-6烷二基；R.sup.4是氢或C.sub.1-6烷氧基；R.sup.5，R.sup.6和R.sup.7各自独立地是氢，卤素，C.sub.1-6烷基，C.sub.1-6烷氧基；或者R.sup.5和R.sup.6也可以一起形成下列结构式的二价基团：--NR.sup.8 C(O)NR.sup.9 --，--NH--C(NHR.sup.10).dbd.N--，--O--(CH.sub.2).sub.m --O--；R.sup.8和R.sup.9各自独立地是氢或C.sub.1-6烷基；R.sup.10是氢，C.sub.1-6烷基羰基，C.sub.1-6烷氧羰基；m为1或2。描述了包括上述化合物的药物组合物、制备化合物和组合物的方法以及用作药物的用途，特别是用于治疗涉及结肠动力减少的肠道疾病。
• [EN] STEREOISOMERIC COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS<br/>[FR] COMPOSES STEREO-ISOMERES ET METHODES DE TRAITEMENT DE TROUBLES GASTRO-INTESTINAUX ET DU SYSTEME NERVEUX CENTRAL
  申请人：ARYX THERAPEUTICS

  公开号：WO2005068461A1

  公开（公告）日：2005-07-28

  The subject invention provides stereoisomeric compounds of formula (X): wherein the variables are as defined herein, and compositions for the safe and effective treatment of various gastrointestinal disorders including, but not limited to, gastroparesis, gastroesophageal reflux and related conditions. The compounds of the subject invention are also useful in treating a variety of conditions involving the central nervous system.

  本发明提供了式（X）的立体异构化合物：其中变量如本文所定义，并提供了用于安全有效治疗各种胃肠道疾病的组合物，包括但不限于胃轻瘫、胃食管反流及相关症状。本发明的化合物还可用于治疗涉及中枢神经系统的各种疾病。
• N-aryl-N-(1-substituted-3-alkoxy-4-piperidinyl)amides and pharmaceutical
  申请人：BOC, Inc.

  公开号：US04994471A1

  公开（公告）日：1991-02-19

  This invention pertains to novel N-aryl-N-[N-substituted 3-alkoxy-4-piperidinyl]amides useful as analgesics, and methods of administering analgesia, which comprises the systemic administration to mammals of such compounds, and pharmaceutical compositions containing such compounds, wherein the novel compounds have the general formula: ##STR1## including optically active isomeric forms, cis/trans isomeric forms and the pharmaceutically acceptable acid addition salts therof, wherein: R is an aryl group selected from the group consisting of phenyl and substituted phenyl, wherein the substituents on the phenyl group are independently selected from the group consisting of halogen, lower-alkyl, lower-alkoxy, and combinations thereof; R.sub.1 is an alkyl group selected from the group consisting of lower-alkyl, lower-alkenyl, and lower-alkoxy lower-alkyl, each alkyl group having from 1 to 6 carbon atoms; R.sub.2 is a member selected from the group consisting of phenyl lower-alkyl, thienyl lower-alkyl, pyrazolyl lower-alkyl, tetrazolyl lower-alkyl, 4,5-dihydro-5-oxo-1H-tetrazolyl lower-alkyl, 1,3-dihydro-1,3-dioxo-2H-isoindolyl lower-alkyl, and 2,3-dihydro-2-oxo-1H-benzimidazolyl lower-alkyl; and R.sub.3 is a member selected from the group consisting of hydrogen, lower-alkyl and lower-alkyl aryl.

  本发明涉及一种新型的N-芳基-N-[N-取代的3-烷氧基-4-哌啶基]酰胺，可用作镇痛剂，以及给哺乳动物系统性给予这些化合物进行镇痛的方法和含有这些化合物的制药组合物，其中这些新型化合物具有以下通式： ##STR1## 包括光学活性异构体形式，顺反异构体形式和药学上可接受的酸盐形式，其中：R是从苯基和取代苯基组成的群体中选择的芳基基团，其中苯基上的取代基独立地选择自卤素，低碳基，低碳氧基和其组合；R.sub.1是从低碳基，低碳烯基和低碳氧基低碳基组成的群体中选择的烷基基团，每个烷基基团具有1至6个碳原子；R.sub.2是从苯基低碳基，噻吩基低碳基，吡唑基低碳基，四唑基低碳基，4,5-二氢-5-氧代-1H-四唑基低碳基，1,3-二氢-1,3-二氧代-2H-异吲哚基低碳基和2,3-二氢-2-氧代-1H-苯并咪唑基低碳基中选择的成员；以及R.sub.3是从氢，低碳基和低碳基芳基中选择的成员。